Brentuximab Drug Information
Available by prescription only, brentuximab vedotin (AdcetrisTM) is licensed to treat Hodgkin's lymphoma and a form of non-Hodgkin's lymphoma called systemic anaplastic large cell lymphoma (ALCL). It comes as an intravenous (IV) injection that is administered by your healthcare provider every three weeks.
Brentuximab vedotin is approved for use in people age 18 and older, and is reserved for use when other forms of chemotherapy have failed. This medicine works by binding to a certain protein within the cancer cells, causing them to die. Studies have shown that brentuximab vedotin can help reduce tumor size.
Before starting chemotherapy treatment with brentuximab vedotin, make sure to review the drug's safety information with your healthcare provider. For example, you may not be able to use this medicine if you have certain allergies, if you are taking certain other medications, or if you are pregnant or breastfeeding.
(For more information on this chemotherapy drug, click Brentuximab Vedotin. This article offers a complete overview, including details on possible side effects, in-depth dosing guidelines, and more.)